The present invention is directed to a personal composition comprising a) a strobilurin; b) salicylic acid wherein the ratio of a:b is from about 1:1 to about 100:1; wherein there is a synergistic anti-inflammatory/cellular stress activity.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly. This invention also provides a pharmaceutical composition comprising an amount of a FABP5 inhibitor and an amount of an anticancer therapy for use in treating a subject afflicted with a cancer, wherein the FABP5 inhibitor and an anticancer therapy are administered sequentially or simultaneously.

This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly. This invention also provides a pharmaceutical composition comprising an amount of a FABP5 inhibitor and an amount of an anticancer therapy for use in treating a subject afflicted with a cancer, wherein the FABP5 inhibitor and an anticancer therapy are administered sequentially or simultaneously.

This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly. This invention also provides a pharmaceutical composition comprising an amount of a FABP5 inhibitor and an amount of an anticancer therapy for use in treating a subject afflicted with a cancer, wherein the FABP5 inhibitor and an anticancer therapy are administered sequentially or simultaneously.

A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.

A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.

The present invention relates to a compound selected from the group consisting of cynarine, eravacycline and prexasertib or a pharmaceutically acceptable salt thereof, preferably eravacycline or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of viral infections by coronavirus selected from the group consisting of MERS-CoV, SARS-CoV and SARS-CoV-2 virus, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.

The present invention relates to a compound selected from the group consisting of cynarine, eravacycline and prexasertib or a pharmaceutically acceptable salt thereof, preferably eravacycline or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of viral infections by coronavirus selected from the group consisting of MERS-CoV, SARS-CoV and SARS-CoV-2 virus, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.